[eGongsi Notice] KOSDAQ - 5 Days

▲Vivozon Healthcare = Due to a paid-in capital increase, the largest shareholder changed from Vivozon and one other to Voltia and one other.

▲J-Way = Resolved the reason for non-submission of the business report, partially lifting the designation as a management item.

▲Motrex = Trading suspension from the 8th to the 28th due to stock consolidation schedule.

▲Chamzon Global = Korea Exchange KOSDAQ Market Division announced that additional reasons for designation as a management item may be added.

▲Taewoong = Korea Exchange KOSDAQ Market Division announced that it is reviewing whether the company falls under the subject of a substantial examination of listing eligibility according to Article 56, Paragraph 1, Subparagraph 3 of the KOSDAQ Market Listing Regulations.

▲Syswork = Korea Exchange KOSDAQ Market Division announced the receipt of an objection to delisting and the granting of an improvement period.

▲HNT = Korea Exchange KOSDAQ Market Division announced that orderly trading has been postponed.

▲HNT = Filed a provisional injunction to suspend the effect of the delisting decision against Korea Exchange.

▲Studio Santa Claus = In response to an inquiry disclosure, stated, "After consulting the largest shareholder, the company is reviewing various strategic options including the sale of its shares, and has selected Samjong Accounting Corporation as an advisor to proceed with necessary preliminary procedures."

▲SL Bionics = In response to an inquiry disclosure, stated, "To improve financial and governance structures, we are promoting the sale of Studio Santa Claus and have selected Samjong Accounting Corporation as an advisor to proceed with necessary preliminary procedures."

▲Redrover = Announced that the bankruptcy petition filed by a creditor at Suwon District Court was dismissed.

▲Skin&Skin = The largest shareholder The Pyeonhan and other major shareholders decided on voluntary lock-up of their shares to ensure management stability and responsible management of Skin&Skin.

▲Vaxcell Bio = Reappointment of outside director Jung Sung-chang.

▲Rimed = Signed a supply contract worth 8.2 billion KRW with Germany's Zimmer MedizinSysteme GmbH for Compact II (electromagnetic field pain treatment device).